Dr. Martina Vincenzi holds a degree in Chemistry and Pharmaceutical Technologies and a Ph.D. in Pharmacology and Toxicology. Over the years, Dr. Vincenzi has contributed to defining the multifaceted roles of prokineticins and their receptors. Her work has demonstrated that dysregulation of the prokineticin system participates in several pathological contexts. Through these studies, she identified prokineticin-2 as a potential biomarker and prokineticin receptors as promising therapeutic targets, revealing novel molecular pathways involved in inflammation and tissue remodeling. Her research extends to the gut–brain axis, where she explores how intestinal dysbiosis, altered neuroimmune signaling, and enteric neuroinflammation can initiate or amplify pathogenic cascades. She also investigates how dietary and microbial interventions can restore intestinal homeostasis and improve systemic health. By integrating molecular, translational, and ecological perspectives, Dr. Vincenzi aims to unravel how disruption of intestinal homeostasis acts as an early driver of multifactorial diseases, including neurodegenerative, cardiovascular, metabolic, and inflammatory disorders. Within the One Health framework, she is particularly interested in how diet, pollution, antibiotics, and zoonotic exchanges disrupt microbial communities and influence gut–brain communication. Her long-term goal is to identify novel microbiome-, lipid- or peptide-targeted therapies.